Epidemiology and seasonal variation in the onset of cirrhosis:analysis of 354 cases in Wuhan union hospital
-
摘要: [目的]探讨武汉协和医院354例肝硬化患者流行病学情况及发病时间是否存在时间规律性, 为进一步防治肝硬化提供依据。[方法]回顾性分析武汉协和医院2009年1月~2014年1月354例肝硬化患者的临床资料, 分析其发病的时间规律性。[结果]本组患者男206例, 占58.19%;女148例, 占41.81%;发病年龄51~60岁为高发年龄段;病因以乙型病毒性肝炎最多见, 占45.19%;肝硬化最常见的并发症是门静脉高压 (96.61%);患者就诊的主要原因是上消化道出血 (40.11%)。肝硬化的总体发病时间以3月份最多。[结论]肝硬化存在3月份发病率上升的时间规律性, 乙肝肝硬化是肝硬化的主要病因之一, 防治病毒性肝炎是预防肝硬化的重要手段。积极防治肝硬化并发症上消化道出血是延长患者生命最重要的环节。Abstract: [Objective] To provide basis for the prevention and treatment for cirrhosis via exploring the epidemiology and the possible existence of a seasonal variability in its onset.[Methods] 354 hospitalized cases of cirrhosis, from January 2009 to January 2014, were retrospectively analyzed for seasonal variation.[Results] The data include 206 male patients (58.19%) and 148 female patients (41.81%).High incidence falls in the age range from 51 to 60 years.Viral hepatitis B is the most common cause of cirrhosis (45.19%).The biggest complication (96.61%) is portal hypertension.The patients were mainly hospitalized for upper gastrointestinal hemorrhage (40.11%).There was significant difference in overall incidence of cirrhosis onset time, March had the highest incidence.[Conclusion] Seasonal pattern in the onset of cirrhosis, with a peak in March, is confirmed.Hepatitis B induced cirrhosis is the main cause of the incidence in Hubei, therefore prevention and treatment of viral hepatitis is an important approach for preventing cirrhosis.Prevention and treatment of its complication, upper gastrointestinal hemorrhage, is the key that prolongs life of patients.
-
Key words:
- cirrhosis /
- epidemiology /
- seasonal variation
-
-
[1] Innes H A, Hutchinson S J, Barclay S, et al.Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients:Implications for treatment cost-effectiveness[J].Hepatology, 2013, 57 (2):451-460.
[2] Ozturk Z A, Kadayifci A.Insulin sensitizers for the treatment of non-alcoholic fatty liver disease[J].World J Hepatol, 2014, 6 (4):199-199.
[3] Beschin A, De Baetselier P, Van Ginderachter J A.Contribution of myeloid cell subsets to liver fibrosis in parasite infection[J].J Pathol, 2013, 229 (2):186-197.
[4] Trautwein C, Friedman SL, Schuppan D, Pinzani M.Hepatic fibrosis:Concept to treatment.J Hepatol, 2015, 62 (1Suppl):S15-24.
[5] Maillard E.Epidemiology, natural history and pathogenesis of hepatocellular carcinoma.Cancer Radiother, 2011, 15 (1):3-6.
[6] Schuppan D, Kim YO.Evolving therapies for liver fibrosis.J Clin Invest, 2013, 123 (5):1887-1901.
[7] 中国中西医结合学会消化系统疾病专业委员会.肝纤维化中西医结合诊疗共识意见 (2017年)[J].中国中西医结合消化杂志, 2017, 25 (12):895-900.
-
计量
- 文章访问数: 322
- PDF下载数: 250
- 施引文献: 0